Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females

Aims Occurrence of metabolic syndrome (MetS) in the United Arab Emirates (UAE) is rising steadily, with subsequent increase in the prevalence of type 2 diabetes and cardiovascular disease (CVD). Recent studies have shown that PCSK9 plays a substantial role in atherogenic dyslipidemia. Hence, the aim of this study was to assess level of PCSK9 and its relationship with MetS components among young adult females. Methods This study was carried out on 137 adult females over 18 years of age residing in the UAE. Subjects were categorized into two groups according to waist circumferences (WC): normal (<80 cm; n = 41) and large (≥80 cm; n = 96). Anthropometric and biochemical parameters in the fasting state (glucose, insulin, lipid profile, and PCSK9) were determined using conventional techniques. Homeostasis model assessment of insulin resistance (HOMA-IR) and MetS scores were calculated as appropriate. Results PCSK9 was lower in subjects with large WC compared to normal WC (p = 0.016). PCSK9 correlated negatively with measures of obesity (p < 0.05), and positively with IR (r = 0.425, p < 0.001). Multiple linear regression analysis revealed that the strongest predictor of PCSK9 was IR (B = 6.213; p < 0.001), followed by WC (B = −2.488; p < 0.001) and triglycerides (B = 0.897; p = 0.013). Conclusion Results from this study demonstrate that PCSK9 correlates with some components of metabolic syndrome and central obesity in young females. Such findings support the suggestion of using PCSK9 inhibitors in the management of MetS to modify risk for development of CVD.